Cargando…

Comparable efficacy and less toxicity of pegylated liposomal doxorubicin versus epirubicin for neoadjuvant chemotherapy of breast cancer: a case-control study

BACKGROUND: Pegylated liposomal doxorubicin (PLD) and epirubicin are both superior variants of doxorubicin and are commonly applied as basic chemotherapeutics in breast cancer. However, the direct comparison of their efficacy and side effects has not been adequately reported. This study aimed to com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Minjun, Luo, Liang, Ying, Xiaogang, Lu, Xianqiu, Shen, Jianguo, Jiang, Zhinong, Wang, Linbo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061676/ https://www.ncbi.nlm.nih.gov/pubmed/30087568 http://dx.doi.org/10.2147/OTT.S162003

Ejemplares similares

Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study
por: Zhang, Jin, et al.
Publicado: (2021)

Pegylated Liposomal Doxorubicin Versus Epirubicin as Adjuvant Therapy for Stage I–III Breast Cancer
por: Hu, Wenxian, et al.
Publicado: (2021)

Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Vici, Patrizia, et al.
Publicado: (2014)

Pegylated liposomal doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo
por: Yuan, Y, et al.
Publicado: (2008)

Pegylated liposomal doxorubicin in ovarian cancer
por: Green, Andrew E, et al.
Publicado: (2006)

Pegylated liposomal doxorubicin in ovarian cancer
por: Strother, Robert, et al.
Publicado: (2009)

Pegylated liposomal doxorubicin for myeloid neoplasms
por: Zhang, Cheng, et al.
Publicado: (2019)

The Efficacy of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Case-Control Study in Taiwan
por: Hung, Chih-Chiang, et al.
Publicado: (2020)

Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin
por: Liu, Weifang, et al.
Publicado: (2021)

Kinetic Targeting of pegylated liposomal Doxorubicin: a new Approach to Reduce Toxicity during Chemotherapy (CARL-trial)
por: Eckes, Jürgen, et al.
Publicado: (2011)

Exploring the Use of Pegylated Liposomal Doxorubicin (Caelyx(®)) as Pressurized Intraperitoneal Aerosol Chemotherapy
por: Robella, Manuela, et al.
Publicado: (2019)

Pegylated liposomal doxorubicin in the management of ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2010)

A tale of the two PEGylated liposomal doxorubicins
por: Chou, Hunghsueh, et al.
Publicado: (2015)

The effect of monosialylganglioside mix modifying the PEGylated liposomal epirubicin on the accelerated blood clearance phenomenon
por: Zhang, Ting, et al.
Publicado: (2017)

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
por: Yuan, Zhen, et al.
Publicado: (2021)

Combination of pegylated liposomal doxorubicin and docetaxel as neoadjuvant therapy for breast cancer with axillary lymph node metastasis
por: Wang, Li, et al.
Publicado: (2020)

Pegylated Liposomal Doxorubicin-induced Palmar-plantar Erythrodysesthesia
por: Moreira-Barros, Joana, et al.
Publicado: (2018)

Prolonged use of pegylated liposomal doxorubicin in gynecologic malignancies
por: Yost, S., et al.
Publicado: (2019)

Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma
por: Ghaferi, Mohsen, et al.
Publicado: (2022)

Pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy in locally advanced breast cancer (registration number: ChiCTR1900023052)
por: Li, Ruoyang, et al.
Publicado: (2019)

A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study
por: Vici, Patrizia, et al.
Publicado: (2011)

Accelerated drug release and clearance of PEGylated epirubicin liposomes following repeated injections: a new challenge for sequential low-dose chemotherapy
por: Yang, Qiang, et al.
Publicado: (2013)

Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer
por: Li, Xin-Ru, et al.
Publicado: (2022)

The efficacy and cardiac toxicity of different‐dose pegylated liposomal doxorubicin in elderly patients with diffuse large B lymphoma
por: Li, Li, et al.
Publicado: (2022)

Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma
por: Udhrain, Ashish, et al.
Publicado: (2007)

Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer
por: Pisano, Carmela, et al.
Publicado: (2013)

Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial
por: Wang, Tiantian, et al.
Publicado: (2022)

Efficacy and toxicity of CLAG combined with pegylated liposomal doxorubicin in the treatment of refractory or relapsed acute myeloid leukemia
por: Yao, Han, et al.
Publicado: (2023)

Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma
por: Schmidinger, M, et al.
Publicado: (2001)

Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi’s sarcoma
por: Cainelli, Francesca, et al.
Publicado: (2009)

Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer
por: Anders, Carey K., et al.
Publicado: (2013)

The role of size in PEGylated liposomal doxorubicin biodistribution and anti‐tumour activity
por: Dadpour, Saba, et al.
Publicado: (2022)

The Efficacy and Toxicity of Neoadjuvant Chemotherapy Regimens of Epirubicin Plus Cyclophosphamide Followed by Docetaxel or Paclitaxel in Female Breast Cancer Patients
por: Wu, Xian, et al.
Publicado: (2021)

Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma
por: Nik, Maryam Ebrahimi, et al.
Publicado: (2019)

Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure
por: Savani, Malvi, et al.
Publicado: (2019)

Cardiac Safety of Pegylated Liposomal Doxorubicin After Conventional Doxorubicin Exposure in Patients With Sarcoma and Breast Cancer
por: Alhaja, Maher, et al.
Publicado: (2023)

FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer
por: CHEN, WENJUN, et al.
Publicado: (2014)

Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar
por: Fracasso, P M, et al.
Publicado: (2005)

The Way that PEGyl-DSPC Liposomal Doxorubicin Particles Penetrate into Solid Tumor Tissue
por: Pan, Xing Qing, et al.
Publicado: (2006)

Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)
por: O’Donnell, Robert T., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_3d12hbbarqnrcn4k8120in5nb2